How High Will Roku Stock Go?
Streaming software and hardware maker Roku (NASDAQ:ROKU) has seen its…
Sell
32
TNXP Quote, Financials, Valuation and Earnings
Last price:
$32.00
Seasonality move
:
-16.81%
Day range:
$31.50 - $34.69
52-week range:
$6.76 - $137.25
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
9.44x
P/B ratio:
1.40x
Volume:
1.3M
Avg. volume:
1.1M
1-year change:
-70.66%
Market cap:
$253M
Revenue:
$10.1M
EPS (TTM):
-$1,963.61
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TNXP
Tonix Pharmaceuticals Holding
|
$2.6M | -$3.09 | 15.49% | -99.42% | $61.67 |
|
ABBV
AbbVie
|
$12.9B | $2.40 | 3.24% | 313.38% | $208.86 |
|
BIVI
BioVie
|
-- | -$0.32 | -- | -38.46% | $6.00 |
|
CGTX
Cognition Therapeutics
|
-- | -$0.12 | -- | -55.56% | $3.25 |
|
COCP
Cocrystal Pharma
|
-- | -$0.51 | -- | -62.26% | $8.33 |
|
PDSB
PDS Biotechnology
|
-- | -$0.25 | -- | -2.9% | $7.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TNXP
Tonix Pharmaceuticals Holding
|
$34.54 | $61.67 | $253M | -- | $0.00 | 0% | 9.44x |
|
ABBV
AbbVie
|
$191.08 | $208.86 | $337.5B | 81.31x | $1.64 | 3.34% | 5.90x |
|
BIVI
BioVie
|
$1.14 | $6.00 | $21.2M | -- | $0.00 | 0% | -- |
|
CGTX
Cognition Therapeutics
|
$0.30 | $3.25 | $18.5M | -- | $0.00 | 0% | -- |
|
COCP
Cocrystal Pharma
|
$1.54 | $8.33 | $15.7M | -- | $0.00 | 0% | 7.78x |
|
PDSB
PDS Biotechnology
|
$1.75 | $7.50 | $80M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TNXP
Tonix Pharmaceuticals Holding
|
-- | -3.184 | -- | 11.24x |
|
ABBV
AbbVie
|
98.01% | -0.472 | 18.88% | 0.48x |
|
BIVI
BioVie
|
-- | 0.691 | -- | -- |
|
CGTX
Cognition Therapeutics
|
-- | -4.020 | -- | -- |
|
COCP
Cocrystal Pharma
|
-- | 2.199 | -- | -- |
|
PDSB
PDS Biotechnology
|
-- | 0.433 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TNXP
Tonix Pharmaceuticals Holding
|
$1.5M | -$15.1M | -114.25% | -121.16% | -622.93% | -$16.6M |
|
ABBV
AbbVie
|
$9.3B | $4B | 5.54% | 81.41% | 17.7% | $1.4B |
|
BIVI
BioVie
|
-- | -$3M | -- | -- | -- | -$1.3M |
|
CGTX
Cognition Therapeutics
|
-- | -$8.7M | -- | -- | -- | -$9.9M |
|
COCP
Cocrystal Pharma
|
-- | -$2.3M | -- | -- | -- | -$2.9M |
|
PDSB
PDS Biotechnology
|
-- | -$9.1M | -- | -- | -- | -$9M |
Tonix Pharmaceuticals Holding vs. Competitors
-
Which has Higher Returns TNXP or ABBV?
AbbVie has a net margin of -692.84% compared to Tonix Pharmaceuticals Holding's net margin of 9.64%. Tonix Pharmaceuticals Holding's return on equity of -121.16% beat AbbVie's return on equity of 81.41%.
Company Gross Margin Earnings Per Share Invested Capital TNXPTonix Pharmaceuticals Holding61.18% -$2.84 $180.4M ABBVAbbVie70.01% $0.72 $71.4B -
What do Analysts Say About TNXP or ABBV?
Tonix Pharmaceuticals Holding has a consensus price target of $61.67, signalling upside risk potential of 78.54%. On the other hand AbbVie has an analysts' consensus of $208.86 which suggests that it could grow by 9.31%. Given that Tonix Pharmaceuticals Holding has higher upside potential than AbbVie, analysts believe Tonix Pharmaceuticals Holding is more attractive than AbbVie.
Company Buy Ratings Hold Ratings Sell Ratings TNXPTonix Pharmaceuticals Holding2 0 0 ABBVAbbVie12 12 0 -
Is TNXP or ABBV More Risky?
Tonix Pharmaceuticals Holding has a beta of 2.090, which suggesting that the stock is 108.982% more volatile than S&P 500. In comparison AbbVie has a beta of 0.498, suggesting its less volatile than the S&P 500 by 50.205%.
-
Which is a Better Dividend Stock TNXP or ABBV?
Tonix Pharmaceuticals Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AbbVie offers a yield of 3.34% to investors and pays a quarterly dividend of $1.64 per share. Tonix Pharmaceuticals Holding pays -- of its earnings as a dividend. AbbVie pays out 257.71% of its earnings as a dividend.
-
Which has Better Financial Ratios TNXP or ABBV?
Tonix Pharmaceuticals Holding quarterly revenues are $2.4M, which are smaller than AbbVie quarterly revenues of $13.3B. Tonix Pharmaceuticals Holding's net income of -$16.8M is lower than AbbVie's net income of $1.3B. Notably, Tonix Pharmaceuticals Holding's price-to-earnings ratio is -- while AbbVie's PE ratio is 81.31x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tonix Pharmaceuticals Holding is 9.44x versus 5.90x for AbbVie. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TNXPTonix Pharmaceuticals Holding9.44x -- $2.4M -$16.8M ABBVAbbVie5.90x 81.31x $13.3B $1.3B
-
Which has Higher Returns TNXP or BIVI?
BioVie has a net margin of -692.84% compared to Tonix Pharmaceuticals Holding's net margin of --. Tonix Pharmaceuticals Holding's return on equity of -121.16% beat BioVie's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TNXPTonix Pharmaceuticals Holding61.18% -$2.84 $180.4M BIVIBioVie-- -$0.15 -- -
What do Analysts Say About TNXP or BIVI?
Tonix Pharmaceuticals Holding has a consensus price target of $61.67, signalling upside risk potential of 78.54%. On the other hand BioVie has an analysts' consensus of $6.00 which suggests that it could grow by 426.32%. Given that BioVie has higher upside potential than Tonix Pharmaceuticals Holding, analysts believe BioVie is more attractive than Tonix Pharmaceuticals Holding.
Company Buy Ratings Hold Ratings Sell Ratings TNXPTonix Pharmaceuticals Holding2 0 0 BIVIBioVie1 0 0 -
Is TNXP or BIVI More Risky?
Tonix Pharmaceuticals Holding has a beta of 2.090, which suggesting that the stock is 108.982% more volatile than S&P 500. In comparison BioVie has a beta of 1.232, suggesting its more volatile than the S&P 500 by 23.154%.
-
Which is a Better Dividend Stock TNXP or BIVI?
Tonix Pharmaceuticals Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioVie offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tonix Pharmaceuticals Holding pays -- of its earnings as a dividend. BioVie pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TNXP or BIVI?
Tonix Pharmaceuticals Holding quarterly revenues are $2.4M, which are larger than BioVie quarterly revenues of --. Tonix Pharmaceuticals Holding's net income of -$16.8M is lower than BioVie's net income of -$2.8M. Notably, Tonix Pharmaceuticals Holding's price-to-earnings ratio is -- while BioVie's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tonix Pharmaceuticals Holding is 9.44x versus -- for BioVie. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TNXPTonix Pharmaceuticals Holding9.44x -- $2.4M -$16.8M BIVIBioVie-- -- -- -$2.8M
-
Which has Higher Returns TNXP or CGTX?
Cognition Therapeutics has a net margin of -692.84% compared to Tonix Pharmaceuticals Holding's net margin of --. Tonix Pharmaceuticals Holding's return on equity of -121.16% beat Cognition Therapeutics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TNXPTonix Pharmaceuticals Holding61.18% -$2.84 $180.4M CGTXCognition Therapeutics-- -$0.14 -- -
What do Analysts Say About TNXP or CGTX?
Tonix Pharmaceuticals Holding has a consensus price target of $61.67, signalling upside risk potential of 78.54%. On the other hand Cognition Therapeutics has an analysts' consensus of $3.25 which suggests that it could grow by 989.51%. Given that Cognition Therapeutics has higher upside potential than Tonix Pharmaceuticals Holding, analysts believe Cognition Therapeutics is more attractive than Tonix Pharmaceuticals Holding.
Company Buy Ratings Hold Ratings Sell Ratings TNXPTonix Pharmaceuticals Holding2 0 0 CGTXCognition Therapeutics3 0 0 -
Is TNXP or CGTX More Risky?
Tonix Pharmaceuticals Holding has a beta of 2.090, which suggesting that the stock is 108.982% more volatile than S&P 500. In comparison Cognition Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock TNXP or CGTX?
Tonix Pharmaceuticals Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cognition Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tonix Pharmaceuticals Holding pays -- of its earnings as a dividend. Cognition Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TNXP or CGTX?
Tonix Pharmaceuticals Holding quarterly revenues are $2.4M, which are larger than Cognition Therapeutics quarterly revenues of --. Tonix Pharmaceuticals Holding's net income of -$16.8M is lower than Cognition Therapeutics's net income of -$8.5M. Notably, Tonix Pharmaceuticals Holding's price-to-earnings ratio is -- while Cognition Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tonix Pharmaceuticals Holding is 9.44x versus -- for Cognition Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TNXPTonix Pharmaceuticals Holding9.44x -- $2.4M -$16.8M CGTXCognition Therapeutics-- -- -- -$8.5M
-
Which has Higher Returns TNXP or COCP?
Cocrystal Pharma has a net margin of -692.84% compared to Tonix Pharmaceuticals Holding's net margin of --. Tonix Pharmaceuticals Holding's return on equity of -121.16% beat Cocrystal Pharma's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TNXPTonix Pharmaceuticals Holding61.18% -$2.84 $180.4M COCPCocrystal Pharma-- -$0.23 -- -
What do Analysts Say About TNXP or COCP?
Tonix Pharmaceuticals Holding has a consensus price target of $61.67, signalling upside risk potential of 78.54%. On the other hand Cocrystal Pharma has an analysts' consensus of $8.33 which suggests that it could grow by 441.13%. Given that Cocrystal Pharma has higher upside potential than Tonix Pharmaceuticals Holding, analysts believe Cocrystal Pharma is more attractive than Tonix Pharmaceuticals Holding.
Company Buy Ratings Hold Ratings Sell Ratings TNXPTonix Pharmaceuticals Holding2 0 0 COCPCocrystal Pharma1 0 0 -
Is TNXP or COCP More Risky?
Tonix Pharmaceuticals Holding has a beta of 2.090, which suggesting that the stock is 108.982% more volatile than S&P 500. In comparison Cocrystal Pharma has a beta of 2.151, suggesting its more volatile than the S&P 500 by 115.085%.
-
Which is a Better Dividend Stock TNXP or COCP?
Tonix Pharmaceuticals Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cocrystal Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tonix Pharmaceuticals Holding pays -- of its earnings as a dividend. Cocrystal Pharma pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TNXP or COCP?
Tonix Pharmaceuticals Holding quarterly revenues are $2.4M, which are larger than Cocrystal Pharma quarterly revenues of --. Tonix Pharmaceuticals Holding's net income of -$16.8M is lower than Cocrystal Pharma's net income of -$2.3M. Notably, Tonix Pharmaceuticals Holding's price-to-earnings ratio is -- while Cocrystal Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tonix Pharmaceuticals Holding is 9.44x versus 7.78x for Cocrystal Pharma. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TNXPTonix Pharmaceuticals Holding9.44x -- $2.4M -$16.8M COCPCocrystal Pharma7.78x -- -- -$2.3M
-
Which has Higher Returns TNXP or PDSB?
PDS Biotechnology has a net margin of -692.84% compared to Tonix Pharmaceuticals Holding's net margin of --. Tonix Pharmaceuticals Holding's return on equity of -121.16% beat PDS Biotechnology's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TNXPTonix Pharmaceuticals Holding61.18% -$2.84 $180.4M PDSBPDS Biotechnology-- -$0.21 -- -
What do Analysts Say About TNXP or PDSB?
Tonix Pharmaceuticals Holding has a consensus price target of $61.67, signalling upside risk potential of 78.54%. On the other hand PDS Biotechnology has an analysts' consensus of $7.50 which suggests that it could grow by 328.57%. Given that PDS Biotechnology has higher upside potential than Tonix Pharmaceuticals Holding, analysts believe PDS Biotechnology is more attractive than Tonix Pharmaceuticals Holding.
Company Buy Ratings Hold Ratings Sell Ratings TNXPTonix Pharmaceuticals Holding2 0 0 PDSBPDS Biotechnology2 0 0 -
Is TNXP or PDSB More Risky?
Tonix Pharmaceuticals Holding has a beta of 2.090, which suggesting that the stock is 108.982% more volatile than S&P 500. In comparison PDS Biotechnology has a beta of 1.272, suggesting its more volatile than the S&P 500 by 27.199%.
-
Which is a Better Dividend Stock TNXP or PDSB?
Tonix Pharmaceuticals Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PDS Biotechnology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tonix Pharmaceuticals Holding pays -- of its earnings as a dividend. PDS Biotechnology pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TNXP or PDSB?
Tonix Pharmaceuticals Holding quarterly revenues are $2.4M, which are larger than PDS Biotechnology quarterly revenues of --. Tonix Pharmaceuticals Holding's net income of -$16.8M is lower than PDS Biotechnology's net income of -$8.5M. Notably, Tonix Pharmaceuticals Holding's price-to-earnings ratio is -- while PDS Biotechnology's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tonix Pharmaceuticals Holding is 9.44x versus -- for PDS Biotechnology. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TNXPTonix Pharmaceuticals Holding9.44x -- $2.4M -$16.8M PDSBPDS Biotechnology-- -- -- -$8.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will The Trade Desk’s Stock Be in 5 Years?
If you stitched together every advertisement The Trade Desk (NASDAQ:…
Is MSTR Stock Fundamentally Misunderstood?
Software firm turned Bitcoin treasury Strategy (NASDAQ:MSTR) has made waves…
Stock Ideas
Buy
65
Is MSFT Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 40x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 48x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 32x
Alerts
Sell
11
VEON alert for Jun 14
VEON [VEON] is down 18.57% over the past day.
Buy
74
DAVE alert for Jun 14
Dave [DAVE] is down 12.68% over the past day.
Buy
54
DAR alert for Jun 14
Darling Ingredients [DAR] is up 9.12% over the past day.
